MedPage Today 
(3/21 Walsh) reports that "the use of antiplatelet therapy among
patients with chronic kidney disease (CKD) does not appear to improve
cardiovascular outcomes and may worsen the likelihood of bleeding,"
according to a systematic review published in the March 20 issue of
Annals of Internal Medicine. Specifically, there was little risk
reduction for myocardial infarction following antiplatelet therapy, but
the risk of major bleeding events did increase. According to the
researchers, the evidence was "low or very low quality"
with "substantial methodological limitations."
(3/21 Walsh) reports that "the use of antiplatelet therapy among
patients with chronic kidney disease (CKD) does not appear to improve
cardiovascular outcomes and may worsen the likelihood of bleeding,"
according to a systematic review published in the March 20 issue of
Annals of Internal Medicine. Specifically, there was little risk
reduction for myocardial infarction following antiplatelet therapy, but
the risk of major bleeding events did increase. According to the
researchers, the evidence was "low or very low quality"
with "substantial methodological limitations."
"We have shown, for the first time, that the potential benefits of
antiplatelet drugs in people with renal disease may actually be
outweighed by the harms, in particular bleeding," senior author Dr.
Giovanni Strippoli told Heartwire
(3/21, Nainggolan). "The trade-off between benefits and harms should
always be carefully assessed before prescribing these [antiplatelet]
drugs to people with CKD," he adds.
(3/21, Nainggolan). "The trade-off between benefits and harms should
always be carefully assessed before prescribing these [antiplatelet]
drugs to people with CKD," he adds.
No comments:
Post a Comment